Compare National Beverage Corp. (FIZZ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Inovio Pharmaceuticals Inc — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.89B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: National Beverage Corp. is far larger — about 25.8× Inovio Pharmaceuticals Inc's market cap, and National Beverage Corp. is more actively traded (553,950 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FIZZ | INO | |
|---|---|---|
Market Cap | $2.89B | $112.19M |
Volume | 553,950 | 3,201,278 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $2.65 |
52-Week Low | $29.20 | $0.66 |
Typical Hold Time | 33 Days | 43 Days |
Enterprise Value | $2.84B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals. The company reported stagnant $1.2B revenue but improved net margins to 15.55% in 2025. Recent earnings misses and a $3.25 special dividend highlight mixed performance. Technical indicators show strong bearish momentum with support at $29 and resistance at $30.
Outlook remains challenged by margin pressure and growth stagnation. While strong profitability metrics (40% ROE) provide support, analyst sentiment is cautious with 50% sell ratings. Key risks include competitive pressures and input cost inflation affecting gross margins.
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
